Hexa Reports

Market Research Reports and Insightful Company Profiles

China Monoclonal Antibody (McAB) Market Share, Size,

Trends, Growth, Research and Development Trend Forecast
2014-2018

Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on
policy environment, global market, Chinese market, as well as the latest developments of domestic key
enterprises related to China's monoclonal antibody industry.
Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and
development of monoclonal antibody agents, which have achieved results in 2013. Hengrui Medicine
Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and Qilu Pharm have applied for clinical research of
monoclonal antibody agents. And Walvax Biotechnology Co., Ltd even made a huge investment in
purchasing Genor Biopharma Co., Ltd, attempting to establish a large biological strategy.
Browse Detail Report With TOC @
http://hexareports.com/report/research-on-china-monoclonal-antibody-mcab-industry-2014/details
Although large-scale pharmaceutical enterprises entered monoclonal antibody field on a large scale, the
overall innovation is still insufficient, and the market is represented by monoclonal antibody agents and
biological analogue that have submitted applications, few imitated drugs, and innovative medicines are
rare and precious things, mainly on account of high risks and long-time cycle.

Hexa Reports
Market Research Reports and Insightful Company Profiles
Due to late state, China's strength on research and development will be still vulnerable within future
three to five years, so it has to open the market preliminarily by depending on generic drugs. In 2013,
the market size was CNY 3.8 billion around, up 30% year-on-year; product categories and sales volume
were far less than that of European and American countries.
According to statistical data of Shanghai Pharmaceutical Profession Association (SPPA), China will see
four to six monoclonal antibody agents by 2016, such as Trastuzumab and Rituximab. And it is expected
by 2020, six to ten monoclonal antibody agents will be listed in market, and some of which are
independently researched drugs. Huidian Research believes that China's monoclonal antibody market
will embrace its first climax from 2017 to 2020.
Table Of Content
1. Overview of Monoclonal Antibody
1.1 Definition and Characteristics
1.2 Preparation Process of Monoclonal Antibody
1.3 Classification
1.4 Mechanism of Action
1.5 Key Technology
Request A Sample copy of This Report @ http://hexareports.com/sample/86366
2. Operation Environment of China's Monoclonal Antibody Industry
2.1 Analysis of Economic Environment
2.2 Policy Analysis
3. Current Situation and Tendencies of Worldwide Monoclonal Antibody Industry
3.1 Development History Overview of International Monoclonal Antibody Market
3.2 Monoclonal Antibody Agents Listing in Market
3.3 Global Key Enterprises Devoting to Developing Monoclonal Antibody Agents
3.4 Powerful Growth Momentum of Global Antibody Market
3.5 Development Tendency and Outlook of Global Monoclonal Antibody Agents
Browse All Pharmaceuticals & Healthcare Market Research Related Reports @
http://hexareports.com/category/pharmaceuticals-and-healthcare-market
4. Operation Situation of China's Monoclonal Antibody Industry
4.1 Small Market Size
4.2 Listing Situation of Monoclonal Antibody Agents
4.3 Comparison of Research Progress between China and Foreign Countries
4.4 The First Climax of Monoclonal Antibody: 2017 to 2020

Hexa Reports
Market Research Reports and Insightful Company Profiles
5. China's Key Monoclonal Antibody Agent Enterprises
5.1 Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ)
5.2 Biotech Pharmaceuticals Co., Ltd.
5.3 Chengdu Huasun Biotechnology Co., Ltd.
5.4 Zhejiang HISUN Pharmaceutical Co., Ltd.
5.5 Shanghai Celgen Biopharmaceutical Co., Ltd.
6. Huge Growth Potential and Development Opportunities of China Monoclonal Antibody Market in
the Future
6.1 Enormous China's Market Space and Potential Medical Demand not Get Satisfied
6.2 Late-Mover Advantage and Unique Opportunity of China Monoclonal Antibody Market
Browse Full Report @
http://hexareports.com/report/research-on-china-monoclonal-antibody-mcab-industry-2014/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
Visit our Blog: http://hexareports.blogspot.com/